vs
Side-by-side financial comparison of Crexendo, Inc. (CXDO) and Protalix BioTherapeutics, Inc. (PLX). Click either name above to swap in a different company.
Crexendo, Inc. is the larger business by last-quarter revenue ($18.1M vs $9.1M, roughly 2.0× Protalix BioTherapeutics, Inc.). Crexendo, Inc. runs the higher net margin — 6.7% vs -60.3%, a 67.1% gap on every dollar of revenue. On growth, Crexendo, Inc. posted the faster year-over-year revenue change (11.2% vs -49.9%). Over the past eight quarters, Crexendo, Inc.'s revenue compounded faster (12.4% CAGR vs -6.7%).
Crexendo, Inc. is a U.S.-headquartered cloud communications technology provider. It delivers unified communications as a service (UCaaS), contact center solutions, business VoIP services, and collaborative work tools, primarily catering to small and medium-sized enterprises operating in the North American market.
Protalix BioTherapeutics is an Israeli pharmaceutical company that manufactures a plant-based enzyme, taliglucerase alfa, which has received U.S. Food and Drug Administration approval for the treatment of Gaucher disease.
CXDO vs PLX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $18.1M | $9.1M |
| Net Profit | $1.2M | $-5.5M |
| Gross Margin | — | 49.4% |
| Operating Margin | 6.3% | -51.1% |
| Net Margin | 6.7% | -60.3% |
| Revenue YoY | 11.2% | -49.9% |
| Net Profit YoY | 140.2% | -184.8% |
| EPS (diluted) | $0.03 | $-0.06 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $18.1M | $9.1M | ||
| Q3 25 | $17.5M | $17.9M | ||
| Q2 25 | $16.6M | $15.7M | ||
| Q1 25 | $16.1M | $10.1M | ||
| Q4 24 | $16.2M | $18.2M | ||
| Q3 24 | $15.6M | $18.0M | ||
| Q2 24 | $14.7M | $13.5M | ||
| Q1 24 | $14.3M | — |
| Q4 25 | $1.2M | $-5.5M | ||
| Q3 25 | $1.4M | $2.4M | ||
| Q2 25 | $1.2M | $164.0K | ||
| Q1 25 | $1.2M | $-3.6M | ||
| Q4 24 | $507.0K | $6.5M | ||
| Q3 24 | $148.0K | $3.2M | ||
| Q2 24 | $588.0K | $-2.2M | ||
| Q1 24 | $434.0K | — |
| Q4 25 | — | 49.4% | ||
| Q3 25 | — | 53.4% | ||
| Q2 25 | — | 62.5% | ||
| Q1 25 | — | 19.1% | ||
| Q4 24 | — | 78.7% | ||
| Q3 24 | — | 53.4% | ||
| Q2 24 | — | 29.8% | ||
| Q1 24 | — | — |
| Q4 25 | 6.3% | -51.1% | ||
| Q3 25 | 7.5% | 11.9% | ||
| Q2 25 | 6.7% | 7.5% | ||
| Q1 25 | 7.2% | -41.0% | ||
| Q4 24 | 3.9% | 39.6% | ||
| Q3 24 | 0.9% | 22.2% | ||
| Q2 24 | 3.9% | -18.0% | ||
| Q1 24 | 3.4% | — |
| Q4 25 | 6.7% | -60.3% | ||
| Q3 25 | 8.3% | 13.2% | ||
| Q2 25 | 7.4% | 1.0% | ||
| Q1 25 | 7.3% | -35.8% | ||
| Q4 24 | 3.1% | 35.6% | ||
| Q3 24 | 0.9% | 18.0% | ||
| Q2 24 | 4.0% | -16.4% | ||
| Q1 24 | 3.0% | — |
| Q4 25 | $0.03 | $-0.06 | ||
| Q3 25 | $0.05 | $0.03 | ||
| Q2 25 | $0.04 | $0.00 | ||
| Q1 25 | $0.04 | $-0.05 | ||
| Q4 24 | $0.03 | $0.10 | ||
| Q3 24 | $0.00 | $0.03 | ||
| Q2 24 | $0.02 | $-0.03 | ||
| Q1 24 | $0.01 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $14.7M |
| Total DebtLower is stronger | $114.0K | — |
| Stockholders' EquityBook value | $63.8M | $48.2M |
| Total Assets | $77.7M | $82.3M |
| Debt / EquityLower = less leverage | 0.00× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $14.7M | ||
| Q3 25 | — | $13.6M | ||
| Q2 25 | — | $17.9M | ||
| Q1 25 | — | $19.5M | ||
| Q4 24 | — | $19.8M | ||
| Q3 24 | — | $27.4M | ||
| Q2 24 | — | $23.4M | ||
| Q1 24 | — | — |
| Q4 25 | $114.0K | — | ||
| Q3 25 | $236.0K | — | ||
| Q2 25 | $356.0K | — | ||
| Q1 25 | $475.0K | — | ||
| Q4 24 | $592.0K | — | ||
| Q3 24 | $709.0K | — | ||
| Q2 24 | $823.0K | — | ||
| Q1 24 | $937.0K | — |
| Q4 25 | $63.8M | $48.2M | ||
| Q3 25 | $61.3M | $52.9M | ||
| Q2 25 | $58.3M | $49.9M | ||
| Q1 25 | $55.2M | $45.2M | ||
| Q4 24 | $51.4M | $43.2M | ||
| Q3 24 | $49.5M | $32.4M | ||
| Q2 24 | $48.2M | $28.6M | ||
| Q1 24 | $46.8M | — |
| Q4 25 | $77.7M | $82.3M | ||
| Q3 25 | $76.0M | $82.3M | ||
| Q2 25 | $71.4M | $78.5M | ||
| Q1 25 | $67.4M | $73.9M | ||
| Q4 24 | $64.9M | $73.4M | ||
| Q3 24 | $62.3M | $61.6M | ||
| Q2 24 | $59.6M | $91.5M | ||
| Q1 24 | $57.5M | — |
| Q4 25 | 0.00× | — | ||
| Q3 25 | 0.00× | — | ||
| Q2 25 | 0.01× | — | ||
| Q1 25 | 0.01× | — | ||
| Q4 24 | 0.01× | — | ||
| Q3 24 | 0.01× | — | ||
| Q2 24 | 0.02× | — | ||
| Q1 24 | 0.02× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $2.3M | $2.0M |
| Free Cash FlowOCF − Capex | — | $1.6M |
| FCF MarginFCF / Revenue | — | 17.8% |
| Capex IntensityCapex / Revenue | 0.0% | 4.4% |
| Cash ConversionOCF / Net Profit | 1.93× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-13.6M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $2.3M | $2.0M | ||
| Q3 25 | $4.4M | $-3.7M | ||
| Q2 25 | $1.3M | $-5.2M | ||
| Q1 25 | $1.2M | $-5.1M | ||
| Q4 24 | $2.2M | $4.0M | ||
| Q3 24 | $1.6M | $4.1M | ||
| Q2 24 | $2.7M | $-3.6M | ||
| Q1 24 | $-166.0K | — |
| Q4 25 | — | $1.6M | ||
| Q3 25 | — | $-4.2M | ||
| Q2 25 | $1.3M | $-5.7M | ||
| Q1 25 | — | $-5.4M | ||
| Q4 24 | $2.1M | $3.6M | ||
| Q3 24 | — | $4.0M | ||
| Q2 24 | — | $-3.8M | ||
| Q1 24 | — | — |
| Q4 25 | — | 17.8% | ||
| Q3 25 | — | -23.7% | ||
| Q2 25 | 7.7% | -36.2% | ||
| Q1 25 | — | -53.0% | ||
| Q4 24 | 13.2% | 19.6% | ||
| Q3 24 | — | 22.4% | ||
| Q2 24 | — | -28.1% | ||
| Q1 24 | — | — |
| Q4 25 | 0.0% | 4.4% | ||
| Q3 25 | 0.0% | 2.8% | ||
| Q2 25 | 0.1% | 2.8% | ||
| Q1 25 | 0.0% | 3.0% | ||
| Q4 24 | 0.2% | 2.3% | ||
| Q3 24 | 0.0% | 0.5% | ||
| Q2 24 | 0.0% | 1.3% | ||
| Q1 24 | 0.0% | — |
| Q4 25 | 1.93× | — | ||
| Q3 25 | 3.05× | -1.58× | ||
| Q2 25 | 1.05× | -31.91× | ||
| Q1 25 | 1.06× | — | ||
| Q4 24 | 4.29× | 0.61× | ||
| Q3 24 | 10.95× | 1.27× | ||
| Q2 24 | 4.51× | — | ||
| Q1 24 | -0.38× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CXDO
| Services | $8.6M | 48% |
| Software Solution Segment | $8.3M | 46% |
| Products | $1.1M | 6% |
PLX
| Products | $8.7M | 95% |
| Other | $428.0K | 5% |
